Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%

Reuters

02/19

Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%

Incannex Healthcare Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602181835NEWSFILECNPR____20260218_284430_1) on February 18, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612453420"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612453420\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612453420?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 07:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612453420","market":"us","top_or_hot":-1,"title":"Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602181835NEWSFILECNPR____20260218_284430_1) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-19 07:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602181835NEWSFILECNPR____20260218_284430_1) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IXHL","symbol_name":"INCANNEX HEALTHCARE LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL31jhZr:1","article_id":"2612453420","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612453420","pubTimestamp":1771457761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incannex Healthcare Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"translate_title":"Incannex重点介绍2期RePOSA数据，显示IHL-42X可将OSA AHI降低高达83%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXHL":0.9},"content_text":"Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%\n    \n\nIncannex Healthcare Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602181835NEWSFILECNPR____20260218_284430_1) on February 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}